Dianthus Therapeutics, Inc. (DNTH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1 | 6 | 3 | 6 | 2 | 2 | 2 |
| Operating profit | $m | -178 | -218 | ||||||
| Net profit | $m | -75 | -13 | -28 | -44 | -85 | -162 | - | -146 |
| EPS reported | $ | -4.20 | -0.53 | ||||||
| Operating cashflow per share | $ | -3.41 | -2.77 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -3.42 | -2.78 | ||||||
| Free cash flow | $m | -129 | -156 | ||||||
| Net debt | $m | -403 | -887 | ||||||
| Book value equity | $m | 493 | 1,172 | ||||||
| Book value per share | $ | 13.05 | 20.92 | ||||||
| Number of shares | m | 37.79 | 56.03 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.16 | 1.33 | ||||||
| P/S LTM | x | 764.98 | 818.01 | ||||||
| P/FCF LTM | x | -12.05 | -10.00 | ||||||
| EV/EBITDA LTM | x | -9.31 | -51.09 | ||||||
| EV/Sales LTM | x | 740.57 | 3,051.91 | ||||||
| Earnings Yield LTM | % | -10.42% | -0.50% | ||||||
| FCF Yield | % | -8.30% | -10.00% | ||||||
| Quality | |||||||||
| ROE | % | -32.90% | -3.51% | ||||||
| ROIC | % | -35.55% | -18.47% | ||||||
| Operating margin | % | -87.39% | -114.41% | ||||||
| Gross margin | % | +100.00% | +96.01% | ||||||
| FCF/Sales | % | -6349.4% | -8178.0% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -67.35% | -69.46% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -93.27 | -120.99 | ||||||
| Net Debt/EBITDA | x | 0.31 | 3.70 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.07% | 0.00% | ||||||
| Net debt/Equity | x | -0.82 | -0.76 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Dianthus Therapeutics, Inc. (DNTH)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free